Internationally, the race to find coronavirus vaccine is turning into a war.&nbsp;

India, on the other hand is secure in its self-knowledge. Whosoever comes up first in this vaccine race, India will be asked for its mass production.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/coronavirus-vaccine-wars-us-accuses-russian-hacker-group-apt29-of-trying-to-steal-data-314092">Coronavirus vaccine wars: US accuses Russian hacker group APT29 of trying to steal data</a>

One out of the three vaccines produced in the world is made in India. This has put India in a special position, but added great responsibility too.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/india-news/indias-cadila-aims-to-complete-trial-of-coronavirus-vaccine-by-march-313985">India's Cadila aims to complete trial of coronavirus vaccine by March</a>

Around the world, there are over 140 vaccine candidates and only 11 so far have reached the stage of human trials.&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-india-the-worlds-vaccine-producer-314138/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

From India, two candidates have made it to the human trials: Bharat Biotech's Covaxin and Zydus Cadila's ZyCoV-D.&nbsp;

India may or may not win this race, but no vaccine would succeed without India.&nbsp;

This is because discovering a vaccine is only half the battle won, the second, an equally important task is to manufacture them in great numbers.&nbsp;

To make vaccine accessible to all countries, mass production would be required with affordable prices.&nbsp;

And this responsibility rests on India's shoulders.&nbsp;

Every year, India produces three billion doses of vaccine and the cost of production and clinical trials are the lowest in the world.&nbsp;

For instance, the vaccine of rotavirus, a gastro-infection that particularly affects children is made 15 times cheaper by India.&nbsp;

The world's largest vaccine manufacturer, Serum Institute of India, makes more than 1.5 billion doses every year and the vaccines are exported to 170 countries.&nbsp;

The institute's role in eradication of polio must also be highlighted.&nbsp;

If Oxford University's COVID-19 vaccine gets a green signal, the company says, in one year, it can produce 700-800 billion doses.&nbsp;

And that too for 13 dollars, the cheapest in the world.&nbsp;

Bill Gates says only India is the country that can produce the vaccine for the entire world.&nbsp;

In April, even China admitted India's pharmaceutical prowess.&nbsp;

Currently, at least six Indian pharmaceutical companies are working with global institutes, which means no just one, but multiple COVID-19 vaccines could be made in India.&nbsp;

To sum it up, the Wuhan virus vaccine, developed anywhere in the world, it will be made in India.&nbsp;

 
&nbsp;

Internationally, the race to find coronavirus vaccine is turning into a war. India, on the other hand is secure in its self-knowledge. Whosoever comes up first in this vaccine race, India will be asked for its mass production.

Internationally, the race to find coronavirus vaccine is turning into a war. India, on the other hand is secure in its self-knowledge. Whosoever comes up first in this vaccine race, India will be asked for its mass production. Also read | Coronavirus vaccine wars: US accuses Russian hacker group APT29 of trying to steal data One out of the three vaccines produced in the world is made in India. This has put India in a special position, but added great responsibility too. Also read | India's Cadila aims to complete trial of coronavirus vaccine by March Around the world, there are over 140 vaccine candidates and only 11 so far have reached the stage of human trials. From India, two candidates have made it to the human trials: Bharat Biotech's Covaxin and Zydus Cadila's ZyCoV-D. India may or may not win this race, but no vaccine would succeed without India. This is because discovering a vaccine is only half the battle won, the second, an equally important task is to manufacture them in great numbers. To make vaccine accessible to all countries, mass production would be required with affordable prices. And this responsibility rests on India's shoulders. Every year, India produces three billion doses of vaccine and the cost of production and clinical trials are the lowest in the world. For instance, the vaccine of rotavirus, a gastro-infection that particularly affects children is made 15 times cheaper by India. The world's largest vaccine manufacturer, Serum Institute of India, makes more than 1.5 billion doses every year and the vaccines are exported to 170 countries. The institute's role in eradication of polio must also be highlighted. If Oxford University's COVID-19 vaccine gets a green signal, the company says, in one year, it can produce 700-800 billion doses. And that too for 13 dollars, the cheapest in the world. Bill Gates says only India is the country that can produce the vaccine for the entire world. In April, even China admitted India's pharmaceutical prowess. Currently, at least six Indian pharmaceutical companies are working with global institutes, which means no just one, but multiple COVID-19 vaccines could be made in India. To sum it up, the Wuhan virus vaccine, developed anywhere in the world, it will be made in India.

As global vaccine race intensifies, India has a crucial responsibility

The much-awaited COVID-19 vaccine developed by the University of Oxford has raised hopes after Phase one human trials showed some encouraging trends.&nbsp;

Blood samples taken from a group of volunteers who were involved in the study showed the vaccine stimulated antibodies and "killer T-cells", the Daily Telegraph reported.

Also read |&nbsp;<a href="https://www.wionews.com/world/8-world-leaders-demand-equal-global-access-to-coronavirus-vaccine-313620">8 world leaders demand equal global access to coronavirus vaccine</a>

Previous research has suggested T-cells can last in the body for years and help combat the viruses.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/indian-pharma-industry-capable-of-producing-covid-19-vaccines-for-entire-world-bill-gates-313652">Indian pharma industry capable of producing COVID-19 vaccines for entire world: Bill Gates</a>

However, some experts also said only further trials could give a clear picture.&nbsp;

"Virtually any vaccine inevitably does this," Danny Altmann, a professor of immunology at the Imperial College London, said, reported Guardian, referring to the generation of antibodies and T-cells.&nbsp;

However, Dr Zania Stamataki, a senior lecturer in viral immunology at the University of Birmingham, said though the questions remains, the findings are a "very encouraging sign".&nbsp;

Some scientists have declined to comment and are waiting for the full publishing of results of the study on medical journal Lancet on Monday.&nbsp;

Also, experts said if the vaccine can generate immunity, the key would be to see for how long the immunity stands.

Recent studies have suggested that patients who have COVID-19 antibodies after getting recovered from the disease saw a signifcant fall in the number of antibodies over the three-month period.&nbsp;

US-based Moderna, producer of another leading COVID-19 vaccine candidate, said on Tuesday that it is all set to kick-off the final stage of human trials on July 27.&nbsp;

The much-awaited COVID-19 vaccine developed by the University of Oxford has raised hopes after Phase one human trials showed some encouraging trends. Blood samples taken from a group of volunteers who were involved in the study showed the vaccine stimulated antibodies and "killer T-cells", the Daily Telegraph reported.

The much-awaited COVID-19 vaccine developed by the University of Oxford has raised hopes after Phase one human trials showed some encouraging trends. Blood samples taken from a group of volunteers who were involved in the study showed the vaccine stimulated antibodies and "killer T-cells", the Daily Telegraph reported. Also read | 8 world leaders demand equal global access to coronavirus vaccine Previous research has suggested T-cells can last in the body for years and help combat the viruses. Also read | Indian pharma industry capable of producing COVID-19 vaccines for entire world: Bill Gates However, some experts also said only further trials could give a clear picture. "Virtually any vaccine inevitably does this," Danny Altmann, a professor of immunology at the Imperial College London, said, reported Guardian, referring to the generation of antibodies and T-cells. However, Dr Zania Stamataki, a senior lecturer in viral immunology at the University of Birmingham, said though the questions remains, the findings are a "very encouraging sign". Some scientists have declined to comment and are waiting for the full publishing of results of the study on medical journal Lancet on Monday. Also, experts said if the vaccine can generate immunity, the key would be to see for how long the immunity stands. Recent studies have suggested that patients who have COVID-19 antibodies after getting recovered from the disease saw a signifcant fall in the number of antibodies over the three-month period. US-based Moderna, producer of another leading COVID-19 vaccine candidate, said on Tuesday that it is all set to kick-off the final stage of human trials on July 27.

COVID-19 vaccine: Oxford university's phase one human trials shows encouraging trends

Unlisted biotech firm CureVac on Wednesday become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in Germany, eyeing potential regulatory approval in mid-2021.

German biotech firm starts human trials of experimental COVID-19 vaccine | WION-DW Partnership

corona-vaccine

Corona Vaccine, News on Corona Vaccine, stories on Corona Vaccine, articles on Corona Vaccine, Corona Vaccine stories at Wion, Corona Vaccine news, Corona Vaccine latest news

corona vaccine

As global vaccine race intensifies, India has a crucial responsibility

COVID-19 vaccine: Oxford university's phase one human trials shows encouraging trends

German biotech firm starts human trials of experimental COVID-19 vaccine | WION-DW Partnership